Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine for Smoking Cessation in Concurrent Alcohol Use Disorder
NCT05729243Phase 4Completed
- Sponsor
- Center for Addiction and Mental Health
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of cytisinicline in Tobacco Use Disorder (TUD), sponsored by Center for Addiction and Mental Health. Started Feb 2023; status: completed.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT05729243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05729243.